South African-based JSE Limited listed Aspen continues to increase the number of lives benefiting from its products, reaching more than 150 countries across the world.
The extensive basket of Aspen products provides treatment for a broad spectrum of acute and chronic conditions experienced throughout all stages of life.
Aspen is a global supplier of branded and generic pharmaceutical products as well as infant nutritional and consumer healthcare products in selected territories. The Group has an extensive global presence with more than 10 000 employees.
With an active presence in some 76 countries, Aspen manufactures approximately 23 billion tablets annually at its 26 manufacturing facilities at 18 sites on 6 continents.
Aspen’s half year gross revenue surged by 47% to R19 billion. CNBC Africa’s David Williams chatted with Aspen Group Chief Executive Stephen Saad about the results.